165 related articles for article (PubMed ID: 36136143)
1. Expression of nectin-4 in papillary renal cell carcinoma.
Zschäbitz S; Mikuteit M; Stöhr C; Herrmann E; Polifka I; Agaimy A; Trojan L; Ströbel P; Becker F; Wülfing C; Barth P; Stöckle M; Staehler M; Stief C; Haferkamp A; Hohenfellner M; Duensing S; Macher-Göppinger S; Wullich B; Noldus J; Brenner W; Roos FC; Walter B; Otto W; Burger M; Schrader AJ; Hartmann A; Erlmeier F; Steffens S
Discov Oncol; 2022 Sep; 13(1):90. PubMed ID: 36136143
[TBL] [Abstract][Full Text] [Related]
2. Expression of Nectin-4 in Chromophobe Renal Cell Carcinoma in a Multicenter Cohort: Early Prognostic and Therapeutic Considerations.
Mikuteit M; Zschäbitz S; Autenrieth M; Weichert W; Hartmann A; Steffens S; Erlmeier F
Oncology; 2024; 102(6):503-509. PubMed ID: 38043528
[TBL] [Abstract][Full Text] [Related]
3. The Prognostic Impact of PD-L2 in Papillary Renal-Cell Carcinoma.
Mondorf Y; Mikuteit M; Ivanyi P; Stöhr C; Herrmann E; Polifka I; Agaimy A; Trojan L; Ströbel P; Becker F; Wülfing C; Barth P; Stöckle M; Staehler M; Stief CG; Haferkamp A; Hohenfellner M; Macher-Göppinger S; Wullich B; Noldus J; Brenner W; Roos FC; Walter B; Otto W; Burger M; Schrader AJ; Hartmann A; Steffens S; Erlmeier F
Urol Int; 2022; 106(11):1168-1176. PubMed ID: 35654002
[TBL] [Abstract][Full Text] [Related]
4. Expression of Prostate-specific Membrane Antigen (PSMA) in Papillary Renal Cell Carcinoma - Overview and Report on a Large Multicenter Cohort.
Zschäbitz S; Erlmeier F; Stöhr C; Herrmann E; Polifka I; Agaimy A; Trojan L; Ströbel P; Becker F; Wülfing C; Barth P; Stöckle M; Staehler M; Stief C; Haferkamp A; Hohenfellner M; Macher-Göppinger S; Wullich B; Noldus J; Brenner W; Roos FC; Walter B; Otto W; Burger M; Schrader AJ; Mondorf Y; Hartmann A; Ivanyi P; Steffens S
J Cancer; 2022; 13(6):1706-1712. PubMed ID: 35399715
[TBL] [Abstract][Full Text] [Related]
5. cMET: a prognostic marker in papillary renal cell carcinoma?
Erlmeier F; Bruecher B; Stöhr C; Herrmann E; Polifka I; Agaimy A; Trojan L; Ströbel P; Becker F; Wülfing C; Barth P; Stöckle M; Staehler M; Stief C; Haferkamp A; Hohenfellner M; Macher-Göppinger S; Wullich B; Noldus J; Brenner W; Roos FC; Walter B; Otto W; Burger M; Schrader AJ; Hartmann A; Mondorf Y; Ivanyi P; Mikuteit M; Steffens S;
Hum Pathol; 2022 Mar; 121():1-10. PubMed ID: 34998840
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Gas 6 as a Prognostic Marker in Papillary Renal Cell Carcinoma.
Mikuteit M; Zschäbitz S; Stöhr C; Herrmann E; Polifka I; Agaimy A; Trojan L; Ströbel P; Becker F; Wülfing C; Barth P; Stöckle M; Staehler M; Stief C; Haferkamp A; Hohenfellner M; Duensing S; Macher-Göppinger S; Wullich B; Noldus J; Brenner W; Roos F; Walter B; Otto W; Burger M; Erlmeier M; Schrader AJ; Hartmann A; Erlmeier F; Steffens S;
Urol Int; 2023; 107(7):713-722. PubMed ID: 37348477
[TBL] [Abstract][Full Text] [Related]
7. Characterization of PD-1 and PD-L1 Expression in Papillary Renal Cell Carcinoma: Results of a Large Multicenter Study.
Erlmeier F; Steffens S; Stöhr C; Herrmann E; Polifka I; Agaimy A; Trojan L; Ströbel P; Becker F; Wülfing C; Barth P; Stöckle M; Staehler M; Stief C; Haferkamp A; Hohenfellner M; Macher-Göppinger S; Wullich B; Noldus J; Brenner W; Roos FC; Walter B; Otto W; Burger M; Schrader AJ; Hartmann A; Ivanyi P;
Clin Genitourin Cancer; 2021 Feb; 19(1):53-59.e1. PubMed ID: 32778505
[TBL] [Abstract][Full Text] [Related]
8. Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance.
Klümper N; Ralser DJ; Ellinger J; Roghmann F; Albrecht J; Below E; Alajati A; Sikic D; Breyer J; Bolenz C; Zengerling F; Erben P; Schwamborn K; Wirtz RM; Horn T; Nagy D; Toma M; Kristiansen G; Büttner T; Hahn O; Grünwald V; Darr C; Erne E; Rausch S; Bedke J; Schlack K; Abbas M; Zschäbitz S; Schwab C; Mustea A; Adam P; Manseck A; Wullich B; Ritter M; Hartmann A; Gschwend J; Weichert W; Erlmeier F; Hölzel M; Eckstein M
Clin Cancer Res; 2023 Apr; 29(8):1496-1505. PubMed ID: 36534531
[TBL] [Abstract][Full Text] [Related]
9. The prognostic impact of Claudin 6 in papillary renal cell carcinoma.
Mikuteit M; Zschäbitz S; Stöhr C; Herrmann E; Polifka I; Agaimy A; Trojan L; Ströbel P; Becker F; Wülfing C; Barth P; Stöckle M; Staehler M; Stief C; Haferkamp A; Hohenfellner M; Macher-Göppinger S; Wullich B; Noldus J; Brenner W; Roos FC; Walter B; Otto W; Burger M; Schrader AJ; Hartmann A; Steffens S; Erlmeier F
Pathol Res Pract; 2022 Mar; 231():153802. PubMed ID: 35180650
[TBL] [Abstract][Full Text] [Related]
10. Nectin-4 is widely expressed in head and neck squamous cell carcinoma.
Sanders C; Lau JF; Dietrich D; Strieth S; Brossart P; Kristiansen G
Oncotarget; 2022 Oct; 13():1166-1173. PubMed ID: 36268557
[TBL] [Abstract][Full Text] [Related]
11. FGFR2 overexpression predicts survival outcome in patients with metastatic papillary renal cell carcinoma.
Tsimafeyeu I; Khasanova A; Stepanova E; Gordiev M; Khochenkov D; Naumova A; Varlamov I; Snegovoy A; Demidov L
Clin Transl Oncol; 2017 Feb; 19(2):265-268. PubMed ID: 27379982
[TBL] [Abstract][Full Text] [Related]
12. Lymphangiogenesis in kidney cancer: expression of VEGF-C, VEGF-D and VEGFR-3 in clear cell and papillary renal cell carcinoma.
Bierer S; Herrmann E; Köpke T; Neumann J; Eltze E; Hertle L; Wülfing C
Oncol Rep; 2008 Oct; 20(4):721-5. PubMed ID: 18813809
[TBL] [Abstract][Full Text] [Related]
13. A Review of Papillary Renal Cell Carcinoma and MET Inhibitors.
Rhoades Smith KE; Bilen MA
Kidney Cancer; 2019 Nov; 3(3):151-161. PubMed ID: 31867475
[TBL] [Abstract][Full Text] [Related]
14. High CENPA expression in papillary renal cell carcinoma tissues is associated with poor prognosis.
Li J; Li Q; Yuan Y; Xie Y; Zhang Y; Zhang R
BMC Urol; 2022 Sep; 22(1):157. PubMed ID: 36163007
[TBL] [Abstract][Full Text] [Related]
15. Characterization of papillary and clear cell renal cell carcinoma through imaging mass cytometry reveals distinct immunologic profiles.
Govindarajan A; Salgia NJ; Li H; Castro DV; Mirzapoiazova T; Armstrong B; Zhao D; Mercier BD; Dizman N; Chawla N; Zengin Z; Meza L; Tripathi N; Sayegh N; Chehrazi-Raffle A; Tripathi A; Pal SK
Front Immunol; 2023; 14():1182581. PubMed ID: 37638025
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic and prognostic tissuemarkers in clear cell and papillary renal cell carcinoma.
Kroeze SG; Bijenhof AM; Bosch JL; Jans JJ
Cancer Biomark; 2010; 7(6):261-8. PubMed ID: 21694464
[TBL] [Abstract][Full Text] [Related]
17. Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models.
Challita-Eid PM; Satpayev D; Yang P; An Z; Morrison K; Shostak Y; Raitano A; Nadell R; Liu W; Lortie DR; Capo L; Verlinsky A; Leavitt M; Malik F; Aviña H; Guevara CI; Dinh N; Karki S; Anand BS; Pereira DS; Joseph IB; Doñate F; Morrison K; Stover DR
Cancer Res; 2016 May; 76(10):3003-13. PubMed ID: 27013195
[TBL] [Abstract][Full Text] [Related]
18. [Clinicopathological features and prognostic analysis of papillary renal cell carcinoma].
Bo ES; Hong P; Zhang Y; Deng SH; Ge LY; Lu M; Li N; Ma LL; Zhang SD
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 54(4):615-620. PubMed ID: 35950382
[TBL] [Abstract][Full Text] [Related]
19. Incidence and long-term prognosis of papillary compared to clear cell renal cell carcinoma--a multicentre study.
Steffens S; Janssen M; Roos FC; Becker F; Schumacher S; Seidel C; Wegener G; Thüroff JW; Hofmann R; Stöckle M; Siemer S; Schrader M; Hartmann A; Kuczyk MA; Junker K; Schrader AJ
Eur J Cancer; 2012 Oct; 48(15):2347-52. PubMed ID: 22698386
[TBL] [Abstract][Full Text] [Related]
20. Type II papillary histology predicts poor outcome in patients with renal cell carcinoma and vena cava thrombus.
Kim KH; You D; Jeong IG; Kwon TW; Cho YM; Hong JH; Ahn H; Kim CS
BJU Int; 2012 Dec; 110(11 Pt B):E673-8. PubMed ID: 22973869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
